Accès ouvert

Identification of SARS-CoV-2 preclinical (in vivo) compounds targeting COVID-19 main protease: A scoping review, meta-analysis and molecular docking studies

Article scientifique 2020 Anglais

Résumé

Abstract Due to the migratory flow of infected people with severe acute respiratory syndrome virus (SARS-CoV-2), the numbers of confirmed cases of coronavirus 2019 (COVID-19) infections is accelerating worldwide and pre-clinical evidence of antiviral agents that can combat this pandemic is still elusive. We identified published SAR-CoV efficacy experiments in which some selected compounds were used to test the reduction of the virus load in mice. We then developed a combined model based on scoping review, meta-analyses, and molecular docking studies to evaluate the effect size of preclinical studies of compounds that have been tested against SARS-CoV. Molecular docking studies of the inhibitors in the active pocket of COVID-19 protease were also performed. Our results identified three SARS-CoV inhibitors i.e. EIDD-2801, GS-5734 and amodiaquine that are excellent options for optimization and drug development to treat or cure COVID-19.

Citer ce document

Ebenezer, O., Jordaan, M., Damoyi, N., Ogunsakin, R., Shapi, M. (2020). Identification of SARS-CoV-2 preclinical (in vivo) compounds targeting COVID-19 main protease: A scoping review, meta-analysis and molecular docking studies. https://doi.org/10.21203/rs.3.rs-31140/v1

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Oluwakemi Ebenezer Maryam Amra Jordaan Nkululeko Damoyi Ropo Ebenezer Ogunsakin Michael Shapi

Statistiques

Consultations : 1

Téléchargements : 0